{"id":23804,"date":"2021-07-05T11:10:14","date_gmt":"2021-07-05T10:10:14","guid":{"rendered":"https:\/\/touchneurology.com\/?post_type=media_gallery&#038;p=23804"},"modified":"2022-02-10T14:38:10","modified_gmt":"2022-02-10T14:38:10","slug":"renato-mantegazza-ean-2021-challenges-in-the-treatment-of-myasthenia-gravis","status":"publish","type":"media_gallery","link":"https:\/\/touchneurology.com\/neuromuscular-diseases\/conference-hub\/renato-mantegazza-ean-2021-challenges-in-the-treatment-of-myasthenia-gravis\/","title":{"rendered":"Renato Mantegazza, EAN 2021: Challenges in the Treatment of Myasthenia Gravis"},"content":{"rendered":"<p>touchNEUROLOGY met with <strong>Renato Mantegazza<\/strong> (Department of Neuroimmunology and Neuromuscular Diseases, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milan, Italy) to discuss the challenges that arise in treating patients with myasthenia gravis.<\/p>\n<p>The abstract entitled: \u2018Safety and Tolerability of Efgartigimod in Patients with Generalized Myasthenia Gravis: Phase 3 ADAPT Study Results\u2019 was presented at the 7th Congress of the European Academy of Neurology (EAN) &#8211; Virtual 2021.<\/p>\n<p><strong>Question<\/strong>:<\/p>\n<ol>\n<li>What are the challenges in the treatment of patients with myasthenia gravis? (0:19)<\/li>\n<\/ol>\n<p><strong>Disclosures<\/strong>: Renato Mantegazza has received funding for Travel or Meeting attendance from, Alexion, Argenx, Biomarin Novartis, Catalyst, Merck Serono, UCB, and for Advisory Board participation from Alexion, Argenx, UCB, Regeneron.<\/p>\n<p><strong>Support<\/strong>: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.<\/p>\n<p><em><strong>Filmed as a highlight of the EAN Congress, Virtual 2021.<\/strong><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>touchNEUROLOGY met with Renato Mantegazza (Department of Neuroimmunology and Neuromuscular Diseases, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milan, Italy) to discuss the challenges that arise in treating patients with myasthenia gravis. The abstract entitled: \u2018Safety and Tolerability of Efgartigimod in Patients with Generalized Myasthenia Gravis: Phase 3 ADAPT Study Results\u2019 was presented at the 7th [&hellip;]<\/p>\n","protected":false},"featured_media":23805,"template":"","class_list":["post-23804","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-neuromuscular-diseases","vocabulary_1-rare-diseases","video_categories-ean-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/23804"}],"collection":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":2,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/23804\/revisions"}],"predecessor-version":[{"id":28615,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/23804\/revisions\/28615"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media\/23805"}],"wp:attachment":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media?parent=23804"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}